Publications by authors named "G Kees Hovingh"
Plasma proteomics improves prediction of coronary plaque progression.
Eur Heart J Cardiovasc Imaging
December 2024
Aims: Coronary computed tomography angiography (CCTA) offers detailed imaging of plaque burden and composition, with plaque progression being a key determinant of future cardiovascular events. As repeated CCTA scans are burdensome and costly, there is a need for non-invasive identification of plaque progression. This study evaluated whether combining proteomics with traditional risk factors can detect patients at risk for accelerated plaque progression.
View Article and Find Full Text PDFAim: Children with heterozygous familial hypercholesterolaemia (HeFH) show greater carotid intima-media thickness (cIMT). Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibody, substantially reduced low-density lipoprotein cholesterol (LDL-C) and modestly reduced lipoprotein(a) in children with HeFH. We investigated evolocumab's effect on cIMT progression.
View Article and Find Full Text PDFArticle Synopsis
- The trans intestinal cholesterol excretion (TICE) pathway is a strategy to lower LDL cholesterol by promoting the direct excretion of cholesterol from enterocytes into feces, which was previously stimulated in mice using hydrophilic bile acids.* -
- A clinical trial tested whether the bile acid ursodeoxycholic acid (UDCA) could increase fecal cholesterol excretion in humans, involving 20 male participants who received either UDCA or a placebo after a run-in with ezetimibe.* -
- Results showed that while UDCA did increase the hydrophilicity of bile acids, it did not elevate fecal neutral sterols nor decrease LDL cholesterol levels, indicating TICE may not be influenced by bile acid hydroph
Article Synopsis
- Inflammation contributes to the development of atherosclerotic cardiovascular disease, and the study aims to explore how inflammatory markers relate to changes in coronary plaque volume measured by coronary CT angiography (CCTA).
- The research involved 161 patients aged 40 and above with stable coronary artery disease, measuring inflammatory markers like IL-6 at the start, and assessing plaque volumes after a year.
- Results showed that higher IL-6 levels were linked to significant increases in total and noncalcified plaque volume, suggesting that targeting IL-6 could help manage plaque progression and cardiovascular risks.